Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

December 19, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Prostate Cancer18F- FluorocholinePSMA PETRadiotherapyProstatectomyTumor of Prostate
Interventions
DRUG

Radiopharmaceutical 18F-JK-PSMA-7

"The Investigational product 18F-JK-PSMA-7 is a diagnostic radiopharmaceutical for use with positron emission tomography.~18F-JK-PSMA-7 is administered as direct intravenous injection. One single administration of 2-4 MBq/kg of 18F-JK-PSMA-7 is scheduled in each patient included in this study."

DRUG

Radiopharmaceutical 18F-Fluorocholine

"The active substance of Comparator is 18F-Fluorocholine. The Comparator will be a 18F-Fluorocholine with a Marketing Authorisation in Italy that will be used in compliance with its Summary of Product Characteristics (SmPC).~18F-Fluorocholine is administrated as direct intravenous injection. One single administration of 18F-Fluorocholine is scheduled in each patient included in this study."

Trial Locations (2)

Unknown

I.R.S.T. Srl Irccs, Meldola

Ospedale Classificato Sacro Cuore - Don Calabria, Negrar

All Listed Sponsors
collaborator

Advice Pharma Group srl

INDUSTRY

lead

ITEL Telecomunicazioni Srl

INDUSTRY

NCT05622162 - Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7 | Biotech Hunter | Biotech Hunter